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Objectives. We sought to evaluate whether patients with unsta-
ble angina undergoing coronary intervention derive particular
clinical benefit from potent platelet inhibition.
Background. Plaque rupture and platelet aggregation are
pathogenetic processes common to unstable angina and ischemic
complications of percutaneous coronary intervention.
Methods. Of the 2,099 patients undergoing a coronary inter-
vention in the Evaluation of 7E3 in Preventing Ischemic Compli-
cations (EPIC) trial, 489 were enrolled with the diagnosis of
unstable angina and randomized to receive placebo, an abciximab
(c7E3) bolus immediately before the intervention or an abciximab
bolus followed by a 12-h infusion. The primary end point was a
composite of death, myocardial infarction (MI) or urgent repeat
revascularization within 30 days of randomization. The occur-
rence of death, MI or any revascularization within 6 months was
also assessed.
Results. Compared with placebo, the bolus and infusion of
abciximab resulted in a 62% reduction in the rate of the primary
end point (12.8% vs. 4.8%, p 5 0.012) among patients with
unstable angina, due primarily to a reduction in the incidences of
death (3.2% vs. 1.2%, p 5 0.164) and MI (9% vs. 1.8%, p 5 0.004).
By 6 months, cumulative death and MI were further reduced by
abciximab (6.6% vs. 1.8%, p 5 0.018 and 11.1% vs. 2.4%, p 5 0.002,
respectively). The magnitude of the risk reduction with abciximab
was greater among the patients with unstable angina than among
other patients in the EPIC trial without unstable angina for the
end points of death (interaction: p 5 0.008 at 30 days, p 5 0.002
at 6 months) and MI (interaction: p 5 0.004 at 30 days, p 5 0.003
at 6 months).
Conclusions. The syndrome of unstable angina identifies pa-
tients who will experience particularly marked reductions in the
risk of death and MI with abciximab during coronary interven-
tion.
(J Am Coll Cardiol 1997;30:149–56)
©1997 by the American College of Cardiology
Plaque fissure or rupture, occurring either spontaneously or as
a result of induced arterial trauma, is a key initiating compo-
nent in the pathogenesis of unstable angina (1,2) and of the
ischemic complications of percutaneous coronary revascular-
ization (3,4). Likely as a consequence of the additive throm-
bogenic stimuli of coronary injury induced by percutaneous
revascularization techniques superimposed on the de novo
plaque fissure in unstable angina, patients undergoing coro-
nary interventional procedures in the setting of unstable
angina are at elevated risk for death, myocardial infarction
(MI) or recurrent ischemia compared with those undergoing
revascularization for stable angina (5–8).
The central role of platelet activity in the development of
ischemic complications in these settings is highlighted by
several studies demonstrating unequivocal clinical benefit de-
rived from therapy with aspirin among patients with unstable
angina (9–12) and those undergoing percutaneous coronary
revascularization (13,14). Yet aspirin is a relatively weak
platelet inhibitor; newer strategies for more profound inhibi-
tion of platelet activity at the injured coronary plaque focus on
the integrin glycoprotein (GP) IIb/IIIa receptor on the platelet
surface membrane, which binds circulating fibrinogen or von
Willebrand factor and cross links adjacent platelets as the final
common pathway to platelet aggregation (15). The monoclonal
antibody 7E3 (Centocor) (16), the first agent of the class
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directed against this receptor, markedly inhibits platelet aggre-
gation in a dose-dependent manner (17,18). A large-scale,
placebo-controlled, randomized trial (Evaluation of 7E3 in
Preventing Ischemic Complications [EPIC]) demonstrated
that administration of abciximab (c7E3 Fab, ReoPro), a
human-murine chimeric Fab fragment of this antibody, for
12 h during and after “high risk” coronary angioplasty or
directional atherectomy, in addition to conventional therapy
with heparin and aspirin, reduced the incidence of death, MI
or urgent repeat revascularization by 35% compared with
conventional therapy over 30 days (19); a 26% reduction in the
need for repeat target vessel revascularization (TVR) over the
subsequent 6 months was also observed (20).
The current analysis was carried out to evaluate the hypoth-
esis that patients with unstable angina undergoing percutane-
ous coronary revascularization in the EPIC trial, in whom both
spontaneous and induced mechanisms of platelet activation
are operative, might achieve particular benefit from platelet
GP IIb/IIIa blockade.
Methods
Patient group. As previously reported (19,20), 2,099 pa-
tients undergoing high risk coronary balloon angioplasty or
directional atherectomy were enrolled at 56 clinical sites
throughout the United States into the EPIC trial. Criteria
constituting high risk status for entry into the trial included
acute or recent MI, unstable angina or complex target lesion
angiographic morphology in association with advanced age,
female gender or diabetes mellitus. Unstable angina was de-
fined by the presence of early (within 7 days) postinfarction
angina, at least two episodes of angina occurring at rest or
angina occurring despite heparin and nitrate therapy. Tran-
sient electrocardiographic ST-T wave changes accompanying
these clinical presentations were required to confirm the
diagnosis of unstable angina. Patients were excluded if they
were over 80 years of age or for known bleeding diatheses, a
major operation within 6 weeks or stroke within the previous 2
years. Patients provided written informed consent, and the
protocol was approved by the Institutional Review Board at
each clinical site.
Study protocol. The study protocol has been previously
described (19). Briefly, patients were treated with aspirin and
a sufficient bolus of heparin to achieve an activated clotting
time (ACT) of 300 to 350 s before and throughout the
coronary intervention. Patients were randomized in a double-
blind fashion to one of three intravenous treatment regimens:
1) placebo bolus followed by placebo infusion for 12 h; 2)
0.25-mg/kg bolus of abciximab followed by placebo infusion for
12 h; or 3) 0.25-mg/kg bolus of abciximab followed by 10-mg/
min infusion of abciximab for 12 h. Coronary angioplasty or
directional atherectomy was carried out according to standard
techniques. Heparin infusion was continued for the 12-h
duration of the study drug, and vascular sheaths remained in
place until 6 h after discontinuation of the study drug infusion
and 4 h after discontinuation of heparin infusion, whichever
occurred later.
Study end points. End point classifications made by a
clinical events committee in blinded manner were used for the
final analyses. The primary efficacy end point of the trial was a
prespecified composite of any of the following events occurring
within 30 days of randomization: death from any cause, MI or
reinfarction, urgent surgical or repeat percutaneous coronary
revascularization for recurrent ischemia, stent implantation to
treat threatened or abrupt closure of the target vessel or
insertion of an intraaortic balloon pump for recurrent ischemia
in patients for whom repeat revascularization was contraindi-
cated. A secondary efficacy end point was the occurrence of
death, MI or any surgical or repeat percutaneous revascular-
ization (urgent or elective) by 6 months after randomization.
Patient treatment allocations remained double-blinded until
completion of 6-month follow-up in all patients. Definitions of
MI have been described previously (19). Bleeding events
occurring during the hospital period were classified as major,
minor or insignificant according to the criteria used in the
Thrombolysis in Myocardial Infarction trial (21). To account
for the influence of red blood cell transfusions on measured
hemoglobin values, estimated decreases in hemoglobin were
adjusted according to the technique suggested by Landefeld et
al. (22).
Economics substudy. A prospective economics substudy
was conducted within the EPIC trial (23). Bills were collected
for the baseline hospital period and for subsequent hospital
admissions within 6 months of study entry. Medicare cost-to-
charge ratios for each study site were used to convert billed
charges to hospital costs, and physician fees were estimated
using the Physician 1994 Medicare Fee Schedule (Cigna).
Data management and statistical analysis. Data were col-
lected on case report forms by study coordinators at the clinical
sites and verified with source medical records by study moni-
tors. Investigators, study coordinators and the trial sponsor
(Centocor) remained blinded to treatment allocation until the
analysis plan and primary end point data entry were finalized.
Categoric variables are summarized by percentages; contin-
uous variables are summarized by medians and interquartile
ranges. Pairwise comparisons of 30-day outcome, 6-month
outcome and bleeding events were performed between each of
the two abciximab treatment groups and the placebo group
according to the intention-to-treat principle (randomized pa-
Abbreviations and Acronyms
ACT 5 activated clotting time
c7E3 5 abciximab
EPIC 5 Evaluation of 7E3 in Preventing Ischemic Complications
trial
EPILOG 5 Evaluation of PTCA to Improve Long-Term Outcome
by c7E3 GPIIb/IIIa Receptor Blockade trial
GP 5 glycoprotein
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TVR 5 target vessel revascularization
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tients) as well as by analysis of only those patients who actually
received the study drug (treated patients). The p values for
dose response were computed by coding the placebo group as
0, the abciximab bolus group as 1 and the abciximab bolus and
infusion group as 2. A trend test was computed using the
generalized log-rank statistic. The p values for pairwise com-
parisons of placebo to abciximab bolus and infusion were
similar to the dose-response p values and are therefore not
presented.
Outcome through 6 months was assessed separately for all
events from baseline to 6 months or for events occurring after
30 days in patients with an initially successful intervention
(defined as achievement of final stenosis ,50% without an
ischemic complication). Events taking place before the 30-day
cutoff in the latter analysis were excluded in order to focus on
clinical benefit incremental to that encompassed by the pri-
mary 30-day end point analysis.
Proportional hazards (Cox) regression models were fit to
test for differences in treatment effects in the unstable angina
subgroup compared with the other patient groups. All patients
were included in the models testing the interaction between
treatment effects and unstable angina. Effects were estimated
for treatment (abciximab bolus and infusion vs. placebo) and
subgroup (unstable angina vs. no unstable angina). A likeli-
hood ratio test was used to test for the significance of
treatment–subgroup interaction for each end point studied
(24).
Economic data are presented as average total costs (hospi-
tal plus physician) by treatment group, separately for the
baseline hospital period and for the combined follow-up
hospital periods. Pairwise comparisons were made between the
abciximab treatment groups and the placebo group using
the Wilcoxon two-sample test among patients treated with the
study drug.
Results
Patient group. Of the total 2,099 patients enrolled in the
EPIC trial, 489 had a diagnosis of unstable angina on entry and
form the basis of this analysis. Study drug was administered to
470 patients; 19 patients did not receive the study agent
because of the operator’s decision not to perform a coronary
intervention (n 5 7), the investigator’s decision to withhold the
study drug (n 5 3), an adverse event or bleeding before study
drug administration (n 5 3), inappropriate randomization
(n 5 2), thrombocytopenia (n 5 2), withdrawal of consent (n 5
1) or inability to obtain the study drug from a pharmacy (n 5
1).
The selected baseline demographic and procedural charac-
teristics of the 489 randomized patients with unstable angina
are summarized in Table 1. There were no important differ-
ences among the treatment groups with respect to baseline or
procedural variables. Activated clotting times tended to be
lower among patients receiving placebo than among those
treated with abciximab, reflecting the previously reported
modest elevation in ACT induced by this platelet GP IIb/IIIa
receptor antagonist (25). Patients with unstable angina more
frequently received preprocedural heparin than did those
without unstable angina (68% vs. 44%), but there were no
other substantial differences between the two groups with
regard to baseline characteristics.
Outcome through 30 days. Clinical efficacy end points
occurring within 30 days of study entry are summarized in
Table 2 for the three treatment groups. Among the 489
patients with unstable angina randomized in the trial, a graded
effect on the rate of the primary composite end point was
observed, with a 39% reduction among patients randomized to
abciximab bolus compared with placebo and a 62% reduction
among patients randomized to abciximab bolus and infusion
(12.5% vs. 7.8% vs. 4.8%, respectively, p 5 0.012 for dose
response). The incidence of MI (particularly Q wave MI) was
significantly diminished by abciximab bolus and infusion, with
a consistent trend toward a reduction in the other components
of the composite end point as well.
The magnitude of benefit derived from abciximab among
patients with unstable angina was more apparent when only
the 470 patients who actually received the study drug were
considered (Table 2). The rate of the primary composite
efficacy end point was decreased by 71% among patients
treated with the abciximab bolus and infusion compared with
those receiving placebo. The relative risk reduction of the most
serious end points of death and MI was 94% with the
abciximab bolus and infusion (11.1% in the placebo group vs.
5.0% in the abciximab bolus group vs. 0.6% in the abciximab
bolus and infusion group; p , 0.001).
Figure 1 illustrates the efficacy of therapy with abciximab
among patients with unstable angina in relation to the outcome
among the other 1,610 patients in the EPIC trial who were
enrolled without the diagnosis of unstable angina. Placebo
group rates of death or MI were higher among the patients
with unstable angina, whereas other end point event rates were
comparable between the two groups. Treatment with abcix-
imab bolus and infusion was particularly effective compared
with placebo in reducing mortality (62% reduction) and MI
(80% reduction) among patients with unstable angina. Tests
for subgroup interactions suggested that the magnitude of the
treatment effect was larger among patients with unstable
angina than among other patients (p 5 0.150 for mortality, p 5
0.035 for MI). The evidence for treatment subgroup interac-
tion was substantially strengthened when only patients treated
with the study agent were considered (p 5 0.008 for mortality,
p 5 0.004 for MI). There were trends toward less reduction in
urgent intervention with abciximab bolus and infusion in
patients with unstable angina than in other patients. Although
there was a 62% proportionate reduction in the 30-day primary
composite end point in the unstable angina group compared
with a 27% reduction in the other patient groups, the differ-
ence in the magnitude of the treatment effect for this end point
did not reach statistical significance (p 5 0.127).
The rates of bleeding complications during the initial
hospital period are contrasted for patients with and without
unstable angina in Table 3. There was a dose-related increase
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in the incidence of major bleeding and the need for blood
transfusions associated with abciximab therapy in the EPIC
trial (19,26), but rates of bleeding complications were not
different among patients with or without unstable angina.
Outcome through 6 months. Clinical follow-up was 98%
complete in the group of patients with unstable angina. Clinical
events occurring between study entry and 6 months among
randomized or treated patients with unstable angina are
summarized in Table 4. Administration of abciximab bolus and
infusion was associated with a substantially lower rate of death
or MI in this patient group over the 6 months after the
coronary intervention; among those actually receiving the
study drug, the relative risk reduction for death or MI by 6
months was 88% (16.6% in the placebo group vs. 8.1% in the
abciximab bolus group vs. 2.0% in the abciximab bolus and
infusion group; p , 0.001). By considering only those ischemic
events occurring beyond the 30-day period of the primary
outcome analysis (Table 5), it is suggested that administration
of abciximab resulted in an amplification over 6 months of the
reduction in death and MI, not merely a maintenance of early
(30-day) benefit. In contrast, there was less long-term effect of
abciximab therapy on the rates of repeat surgical or percuta-
neous coronary revascularization in patients with unstable
angina (Tables 4 and 5). The incidence of “clinical restenosis,”
as determined by the need for TVR, was not significantly
reduced by abciximab among patients with unstable angina in
this trial.
Figure 2 compares the patients with unstable angina with
those without unstable angina in the EPIC trial with regard to
the 6-month efficacy of abciximab bolus and infusion. As with
the 30-day end point (Fig. 1), placebo group event rates
occurred with roughly equal frequency in the two patient
groups, except for a substantially higher incidence of death in
patients with unstable angina. Death and MI events over 6
months were reduced chiefly among the patients with unstable
angina: the clinical benefit imparted by abciximab bolus and
infusion was greater among patients with unstable angina than
among those without unstable angina for the end points of
death (interaction between unstable angina and treatment
effect: p 5 0.002 for treated patient analysis), MI (p 5 0.003)
and death or MI (p , 0.001). In contrast, long-term benefit in
terms of a diminished necessity for repeat coronary revascu-
larization and a reduction in clinical restenosis appeared
largely confined to those patients without unstable angina.
Economic analysis. Hospital cost data were obtained in
96% of patients with unstable angina in the trial. Average costs
for the baseline hospital period among the 470 patients with
unstable angina actually receiving the study drug were
Table 1. Baseline and Procedural Characteristics of Patients With Unstable Angina in the EPIC Trial
Variable
Placebo
(n 5 156)
Abciximab
Bolus
(n 5 168)
Abciximab Bolus
and Infusion
(n 5 165)
Total
(n 5 489)
Age (yr) 63 (54–69) 61 (53–69) 60 (50–67) 61 (52–68)
Weight (kg) 84 (73–92) 83 (71–93) 80 (71–91) 82 (71–92)
Male gender 65 65 68 66
Diabetes mellitus 21 24 24 23
Hypertension 54 59 54 55
Elevated cholesterol 53 61 48 54
History of smoking 71 71 74 72
Peripheral vascular disease 9 9 12 10
Previous myocardial infarction 54 59 63 59
Previous coronary angioplasty 22 22 17 20
Previous bypass surgery 13 14 10 12
Single-vessel coronary artery disease 55 52 61 56
Interventional procedure
Balloon angioplasty 93 89 86 89
Atherectomy 5 5 7 6
Both 2 5 7 5
Target artery
LAD 42 38 43 41
LCx 22 28 27 26
RCA 35 40 30 35
Bypass graft 4 4 5 4
Preprocedural heparin therapy 69 64 71 68
Thrombolytic agent used 4 5 1 3
Duration of procedure (min) 54 (33–82) 58 (41–87) 53 (32–78) 55 (35–83)
Contrast agent used (ml) 200 (140–270) 200 (150–275) 200 (150–275) 200 (150–275)
Preintervention ACT (s) 348 (299–405) 380 (336–435) 403 (339–454) 377 (326–440)
Dichotomous variables are expressed as percent of total and continuous variables as median (interquartile range).
ACT 5 activated clotting time; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery;
RCA 5 right coronary artery.
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$13,929 6 6,474 vs. $15,072 6 18,374 for the abciximab bolus
and infusion group compared with the placebo group, respec-
tively (p 5 0.130). The cost of abciximab is not included in this
estimate, as the study drug was provided free of charge during
the trial. Average hospital costs over the subsequent 6-month
follow-up period were $3,508 6 8,889 versus $4,625 6 9,893 in
the abciximab bolus and infusion group and placebo group,
respectively (p 5 0.430). Total hospital costs for the patients
with unstable angina in the EPIC trial therefore tended to be
reduced by an average of $2,170 (p 5 0.355) by therapy with
abciximab.
Discussion
Despite considerable research into pharmacologic and re-
vascularization treatments for the acute coronary ischemic
syndromes, outcome among patients hospitalized with unsta-
ble angina remains unsatisfactory. Recently reported large-
scale randomized trials, for example, have demonstrated that
the risk of death or MI within the first 4 to 6 weeks after
development of unstable angina is as high as 9% to 11%
(27,28). Although percutaneous myocardial revascularization
has been advocated as a means of reducing morbidity in this
group of patients, particularly those with symptoms refractory
to medical therapy (29), several studies have suggested that
patients undergoing a coronary intervention in the setting of
unstable angina are at elevated risk for ischemic complications
compared with patients treated by revascularization for more
stable indications (5–8).
The current study evaluated clinical outcome in the sub-
group of 489 patients who met rigorous criteria for unstable
angina in the randomized, placebo-controlled EPIC trial as-
sessing the efficacy of a new potent antiplatelet agent, the GP
IIb/IIIa receptor antagonist abciximab, in preventing ischemic
complications associated with percutaneous coronary interven-
tion. Nearly 11% of the patients with unstable angina who
received placebo in the trial died or had an MI within 30 days
of study enrollment, confirming the high risk profile of this
patient group. Treatment of these patients with abciximab
during and for 12 h after coronary revascularization, however,
resulted in an extraordinary and durable improvement in the
prognosis for this disease process, with a relative reduction in
the incidence of death or MI by 94% over the first 30 days and
by 88% over 6 months. The magnitude of benefit with regard
to these two most serious clinical end points was substantially
greater among patients with unstable angina than among those
undergoing coronary revascularization for stable ischemic
symptoms. These findings support the concept that potent
platelet inhibition by GP IIb/IIIa receptor blockade more
completely attenuates ischemic risk among patients undergo-
Figure 1. Comparison of relative reductions in 30-day end point events
by abciximab bolus and infusion (c7E3 B1I) among randomized
patients with (n 5 489, open squares) and without (n 5 1,601, solid
squares) unstable angina. A hazard ratio of 1 denotes no clinical
benefit of abciximab bolus and infusion for a particular end point; a
hazard ratio ,1 denotes a reduction of risk with abciximab therapy;
and a hazard ratio .1 denotes higher risk with abciximab. Confidence
intervals (95%) intersecting a hazard ratio of 1 represent a nonsignif-
icant influence of abciximab on outcome. Of note is that three deaths
in the abciximab bolus and infusion group (two patients with unstable
angina and one patient without unstable angina) were among patients
who were randomized but did not receive the study drug. Composite 5
death, MI, urgent repeat revascularization (Revasc) for ischemia or
stent or intraaortic balloon pump placement.
Table 2. Thirty-Day Outcome Among Patients With Unstable
Angina in the EPIC Trial
Placebo
Abciximab
Bolus
Abciximab
Bolus and
Infusion
p Value for
Dose
Response
Randomized patients
(n 5 489)
156 168 165
Primary end point (%) 12.8 7.8 4.8 0.012
Death 3.2 0.6 1.2 0.164
MI 9.0 4.2 1.8 0.004
Q wave MI 4.5 0.6 0 0.002
Non–Q wave MI 4.5 4.2 1.8 0.197
Urgent PTCA 3.9 1.8 1.8 0.238
Urgent CABG 3.8 2.4 1.2 0.129
Urgent PTCA or CABG 5.8 4.2 3.0 0.223
Treated patients (n 5 470) 153 161 156
Primary end point (%) 13.1 8.1 3.8 0.004
Death 3.3 0.6 0 0.011
MI 9.2 4.3 0.6 0.001
Q wave MI 4.6 0.6 0 0.002
Non–Q wave MI 4.6 4.3 0.6 0.052
Urgent PTCA 4.0 1.9 1.9 0.259
Urgent CABG 3.9 2.5 0.6 0.057
Urgent PTCA or CABG 5.9 4.4 2.6 0.145
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty or atherectomy.
153JACC Vol. 30, No. 1 LINCOFF ET AL.
July 1997:149–56 Abciximab IN UNSTABLE ANGINA AND REVASCULARIZATION
ing a coronary intervention for unstable angina, in whom
periprocedural complications are most likely to be related to
the thrombotic milieu present before the intervention at the
complex arterial plaque, than among patients with stable
ischemic syndromes, in whom adverse sequelae of percutane-
ous revascularization may be more frequently associated with
mechanical arterial disruption. Enhanced clinical benefit ob-
served in patients with unstable angina was not associated with
a heightened gradient of risk; hemorrhagic complications were
more frequent as a result of abciximab administration (19,26)
but occurred with roughly equal frequency among patients with
and without unstable angina.
Antithrombotic approaches to unstable angina. Amplifi-
cation of the clinical benefit derived from platelet GP IIb/IIIa
receptor blockade among patients with unstable angina in the
EPIC trial is concordant with data from earlier studies empha-
sizing the key role of platelet activity in the pathogenesis of
unstable angina and its ischemic complications. Of the various
pharmacologic strategies that have been tested for efficacy in
the management of unstable angina, those directed at inhibi-
tion of platelet aggregation have been most consistently asso-
ciated with an unequivocal therapeutic benefit, with a relative
reduction in the risk of progression to death or MI of 30% to
50% by aspirin in placebo-controlled trials (9–12). Data sup-
porting such a role for other antithrombotic approaches have
thus far been less reproducible. Randomized studies did not
demonstrate a durable reduction in death or MI among
patients treated with heparin (12,30), low molecular weight
heparin (28), the direct thrombin inhibitors hirudin (31) and
hirulog (32) or thrombolytic agents (27,33) in the setting of
unstable angina.
Repeat revascularization. Notably, the enhancement of
clinical benefit observed among patients with unstable angina
treated with abciximab in the EPIC trial was largely confined to
a reduction of death and MI. Repeat revascularization events,
particularly those occurring over the 6-month period after the
baseline hospital period, were less effectively suppressed by
abciximab in patients with unstable angina than in those
without unstable angina. A possible explanation for this obser-
vation is that the 18- to 24-h period of intense platelet
inhibition produced by the 12-h abciximab infusion (18) may
have been too short to completely attenuate the exaggerated
Table 3. Bleeding Complications and Hematologic Values for
Patients With and Without Unstable Angina in the EPIC Trial
Placebo
Abciximab
Bolus
Abciximab
Bolus and
Infusion
p Value
for Dose
Response
Patients with unstable
angina (n 5 489)
156 168 165
Major bleeding (%)* 4.5 7.7 9.7 0.075
Blood transfusions
(%)*
9.6 10.1 15.8 0.087
Nadir hemoglobin 12.0 11.4 11.0 0.021
(mg/dl)† (10.4, 12.9) (9.9, 12.5) (9.6, 12.4)
Patients without unstable
angina (n 5 1,610)
540 527 543
Major bleeding (%)* 3.0 8.9 10.9 ,0.001
Blood transfusions
(%)*
3.5 12.0 13.1 ,0.001
Nadir hemoglobin 12.0 11.7 11.4 ,0.001
(mg/dl)† (10.7, 13.1) (10.0, 12.8) (9.8, 12.8)
*Major bleeding and blood transfusions unrelated to coronary artery bypass
graft surgery. †Adjusted for transfusions by the Landefeld index (22). Nadir
hemoglobin values are medians (25th and 75th percentiles).
Table 4. Outcome Among Patients With Unstable Angina From
Study Entry Through 6 Months
Placebo
Abciximab
Bolus
Abciximab
Bolus and
Infusion
p Value
for Dose
Response
Randomized Patients (n 5 489) 156 168 165
Composite end point (%) 35.0 26.9 25.4 0.045
Death 6.6 1.2 1.8 0.018
MI 11.1 6.6 2.4 0.002
PTCA 19.5 16.2 15.6 0.361
CABG 11.4 10.3 8.7 0.404
PTCA or CABG 26.1 23.4 23.6 0.556
Target vessel repeat
revascularization (%)
22.0 19.9 18.7 0.480
Treated patients (n 5 470) 153 161 156
Composite end point (%) 35.0 26.8 24.3 0.024
Death 6.7 1.2 0.7 0.002
MI 11.3 6.9 1.3 ,0.001
PTCA 19.9 16.3 15.1 0.254
CABG 10.9 9.5 7.8 0.340
PTCA or CABG 26.0 23.2 23.0 0.466
Target vessel repeat
revascularization (%)
22.2 19.8 18.3 0.410
Abbreviations as in Table 2.
Table 5. Outcome Among Patients With Unstable Angina From 30
Days Through 6 Months
Placebo
Abciximab
Bolus
Abciximab
Bolus and
Infusion
p Value
for Dose
Response
Randomized patients (n 5 418) 125 149 144
Composite end point (%) 20.2 18.1 16.8 0.463
Death 3.5 0.6 0.6 0.049
MI 2.3 2.6 0.6 0.283
PTCA 12.1 13.7 10.2 0.614
CABG 6.5 6.4 6.4 0.969
PTCA or CABG 16.4 17.5 16.6 1.000
Target vessel repeat
revascularization (%)
17.5 17.1 15.9 0.762
Treated patients (n 5 405) 123 143 139
Composite end point (%) 20.5 18.2 17.4 0.508
Death (%) 3.5 0.6 0.7 0.053
MI (%) 2.3 2.7 0.7 0.295
PTCA (%) 12.3 13.6 10.5 0.637
CABG (%) 6.6 6.0 6.0 0.842
PTCA or CABG (%) 16.6 17.6 17.1 0.941
Target vessel repeat
revascularization (%)
17.7 17.0 15.5 0.661
Abbreviations as in Table 2.
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local platelet activity and arterial thrombus formation in these
patients with unstable angina. Large-scale clinical trials are
currently under way to test the potential for prolonged therapy
(1 to 3 days) with GP IIb/IIIa receptor antagonists to achieve
greater clinical benefit in patients with unstable angina. Alter-
natively, repeat revascularization events in the setting of
unstable angina may represent a shift toward less severe and
more stable manifestations of coronary artery disease pro-
duced by therapy with abciximab in patients who otherwise
would have died or had an MI. Finally, it is conceivable that
mechanical factors at the lesion site, such as greater plaque
instability or a heightened propensity for arterial spasm and
recoil, rather than mechanisms mediated by the platelet–
thrombus, may play a dominant role in the process of arterial
renarrowing in patients with unstable angina. In this regard,
stent implantation with concomitant abciximab therapy among
patients with unstable angina may be a most effective means of
limiting both the ischemic and repeat revascularization events
among patients with unstable angina. The potential comple-
mentarity of glycoprotein IIb/IIIa inhibition in the setting of
elective stent implantation was not addressed in the EPIC
study, in which planned stenting was an exclusion criterion, but
is the subject of the ongoing Evaluation of PTCA to Improve
Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade
(EPILOG) stent trial.
Economic impact. Because of the suppression of clinical
ischemic events, treatment with abciximab in patients with
unstable angina in the EPIC trial was associated with an
apparent reduction in economic hospital costs by $2,170 over
the 6-month period after trial entry. This difference in costs
between treatment groups did not reach statistical significance
(p 5 0.355), reflecting the wide variability among patients and
the relatively small size of the unstable angina cohort within
the trial, but nevertheless compares favorably with the $1,231
cost reduction estimated for the overall trial group (23). With
the mean wholesale pharmacy cost per dose of commercially
available abciximab (ReoPro) of $1,407 (23), potential net cost
savings would be approximately $763; use of abciximab in
patients with unstable angina undergoing a coronary interven-
tion may thus be a “dominant strategy” from the economic
standpoint (“dominant strategy” defined as one that reduces
both clinical events and cost). Moreover, with bleeding rates
associated with abciximab reduced below levels observed in the
EPIC trial by modification of heparin dosing and other mea-
sures, as observed in the recent EPILOG trial (34), the
economic profile of this therapy in patients with unstable
angina may be even more favorable.
Study limitations. Although the entry criteria for unstable
angina in the EPIC trial were precisely defined and the
patients with unstable ischemic syndromes constituted one of
the few subgroups prospectively identified for evaluation, any
such subgroup analysis within a randomized trial is subject to
the limitation that apparent differences in treatment effect in
one subset of patients versus another may merely be a spurious
finding due to chance. In fact, differences in treatment benefit
cannot be assessed by simply determining whether p values for
treatment effect are “more significant” in one patient subset
than another; these p values are influenced not only by the
magnitude of the treatment effect, but also by the sample size
of the patient group under evaluation, and thus provide a very
limited perspective on the differences in treatment effect
between subsets of a study group. In the current study,
however, the interaction between treatment effect and unstable
angina was formally tested by Cox proportional hazards regres-
sion modeling, demonstrating that the magnitude of clinical
benefit with abciximab in reducing death or MI by 30 days and
6 months was strongly associated with the presence of unstable
angina.
Conclusions. The adoption of new medical therapeutics
that may be associated with safety risk and economic cost will
optimally be focused on those patients who are likely to
experience the greatest clinical benefit. Although the EPIC
trial established efficacy of therapy with abciximab among
patients considered to be at “high risk” for coronary interven-
tion according to a number of different criteria, it is the clinical
syndrome of unequivocal unstable angina that appears to
identify a group of patients who are at high risk for death or MI
and who will experience a particularly marked improvement in
outcome with adjunctive platelet inhibition by abciximab.
Administration of abciximab holds promise as an effective
means of allowing coronary revascularization to be carried out
Figure 2. Comparison of relative reductions in 6-month end point
events by abciximab bolus and infusion (c7E3 B1I) among random-
ized patients with (n 5 489, open squares) and without (n 5 1,610,
solid squares) unstable angina. See Figure 1 for explanation of hazard
ratios. TV Revasc 5 target vessel revascularization by coronary artery
bypass graft surgery (CABG) or percutaneous transluminal coronary
angioplasty.
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in a safe, expeditious and cost-effective manner in patients with
unstable ischemic syndromes.
We thank Susan FitzPatrick (Centocor, Inc., Malvern, Pennsylvania) for statis-
tical programming support.
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